Pegasus' DermADAPT dressing:
This article was originally published in Clinica
Advanced biologic scaffolds maker Pegasus Biologics has entered the wound care market, after receiving US FDA 510(k) market clearance for its collagen-based DermADAPT biomatrix dressing. Approved for the local management of moderate to heavy exuding wounds, the product will be initially targeted to the diabetic foot ulcer market; in the US alone, five million diabetic patients suffer from foot ulcers, according to the privately held, Irvine, California firm. DermADAPT is strong and stable, maintaining an ideal environment for wound healing, said the company. It is also thin and pliable, and conforms well to the wound bed. Pegasus already sells a product for repairing ligaments and tendons, OrthADAPT bioimplant.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.